Given the frequently observed immune alterations in CLL and the limited understanding of SARS-CoV-2-specific responses in treatment-naive patients, we quantified SARS-CoV-2-specific antibody responses and examined their relationship to levels of total IgM, IgG, and IgA. The gene discussed is CD79A; the disease is B-cell chronic lymphocytic leukemia.